0001193125-23-041459.txt : 20230217 0001193125-23-041459.hdr.sgml : 20230217 20230217060736 ACCESSION NUMBER: 0001193125-23-041459 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230216 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ambrx Biopharma Inc. CENTRAL INDEX KEY: 0001836056 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 571147346 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40505 FILM NUMBER: 23640198 BUSINESS ADDRESS: STREET 1: 10975 NORTH TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 729-3339 MAIL ADDRESS: STREET 1: 10975 NORTH TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 d440404d8k.htm 8-K 8-K
NYSE 00-0000000 false 0001836056 0001836056 2023-02-16 2023-02-16 0001836056 us-gaap:PhantomShareUnitsPSUsMember 2023-02-16 2023-02-16 0001836056 dei:AdrMember 2023-02-16 2023-02-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

February 16, 2023

Date of Report (Date of earliest event reported)

 

 

Ambrx Biopharma Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Cayman Islands   001-40505   N/A

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

10975 Torrey Pines Road

La Jolla, California

   92037
(Address of principal executive offices)   (Zip Code)

(858) 729-3339

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, par value US $0.0001 per share   N/A   The New York Stock Exchange *
American Depositary Shares, each representing seven ordinary shares, par value US $0.0001 per share   AMAM   The New York Stock Exchange

Indicate by check mark

 

*

Not for trading, but only in connection with the listing of the American depositary shares on the New York Stock Exchange. The American depositary shares represent the right to receive the ordinary shares and are being registered under the Securities Act of 1933 pursuant to a separate Registration Statement on Form F-6. Accordingly, the American depositary shares are exempt from registration under Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 8.01.

Other Events.

On February 16, 2023, Ambrx Biopharma Inc. (the “Company”) announced encouraging initial data from its ongoing Phase 1 trial (“APEX-01”) investigating ARX517, the Company’s proprietary anti-prostate-specific membrane antigen (“PSMA”) antibody drug conjugate (“ADC”), in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have progressed on at least two prior Food and Drug Administration (“FDA”)-approved treatments. APEX-01 is the only ongoing clinical trial in the United States targeting PSMA with an ADC. APEX-01 opened for enrollment July 2021 and this is the first data being reported in the study.

In the Phase 1 dose-escalation portion of the study, ascending dose levels of ARX517 is administered as a single agent every 3 weeks. The primary endpoints are safety, tolerability and pharmacokinetics. The key secondary endpoint is objective decline of prostate-specific antigen (“PSA”) from baseline and/or tumor shrinkage. PSA is a protein produced by the prostate gland and is commonly used as a biomarker to diagnose and follow prostate cancer. A ≥ 50% reduction in PSA levels from baseline is considered clinically relevant and has been shown to correlate with improved overall survival in prostate cancer.

To date, 22 prostate cancer patients have been dosed across seven dose level Cohorts starting from 0.32 mg/kg to 2.4 mg/kg. A minimum of three patients were enrolled at each Cohort. The dose limiting toxicity (“DLT”) period is 21 days.

 

  •  

Of 22 patients evaluable for safety, no drug-related severe adverse events (“SAE”) or grade ≥3 treatment-related adverse events (“AE”) have been observed. ARX517 was well-tolerated with grade 1 or 2 treatment-related adverse events being reported. The maximum tolerated dose (“MTD”) has not yet been reached.

 

  •  

PSA reductions of > 30% have been observed in Cohorts 2-5, beginning at the second to lowest dose, 0.64 mg/kg.

 

  •  

In Cohort 6 (2.0 mg/kg dose), three of three (100%) patients experienced a greater than 50% reduction in PSA levels. Two of three patients experienced a greater than 90% reduction of PSA levels. One of three patients had soft tissue measurable disease and experienced a RECIST v1.1 partial response at the first on-treatment scan.

 

  •  

Three patients have been dosed in Cohort 7 with no DLTs.

The Safety Monitoring Committee (“SMC”) meeting to discuss the next dose Cohort is scheduled for the end of February 2023. Not all patients have undergone or completed tumor assessments and the data are not yet final.

The Company plans to report further information regarding ARX517 and the APEX-01 study at its upcoming Analyst and Investor Day scheduled for February 24, 2023. Additional data are planned for presentation at an upcoming medical meeting.

ARX517 is an ADC composed of a fully humanized anti-PSMA monoclonal antibody (“mAb”) linked to AS269, a proprietary potent microtubule inhibitor. ARX517 targets the PSMA. PSMA is highly expressed (>89%) in Metastatic castration-resistant prostate cancer (“mCRPC”) and has been shown to be a validated therapeutic target.

Upon binding to PSMA on the surface of cancer cells, ARX517 is internalized and pAF-AS269, its cancer cell killing payload, is released following lysosomal metabolism. ARX517’s site-specific linkage, stable conjugation chemistry, and non-cleavable linker exhibit a homogenous drug-antibody-ratio, mAb-like biophysical properties and exceptional stability. Therefore, the Company believes ARX517 can promote highly specific tumor cell killing with minimal off-target toxicity.

ARX517 has the potential to be a first- and best-in-class anti-PSMA ADC addressing the high unmet medical need in mCRPC.

The Company issued a press release, dated February 16, 2023 related to the foregoing data, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and such information shall not be deemed incorporated by reference into any other

filing with the Securities and Exchange Commission (“SEC”) made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Forward-Looking Statements

This Current Report on Form 8-K includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “believe,” “intend,” “plan,” “potential,” and similar expressions, and include, without limitation, express or implied statements regarding the Company’s beliefs and expectations regarding the potential benefits of ARX517, clinical development and strategic plans for ARX517 and the timing of trial and data updates and milestones related to ARX517. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on the Company’s business, operations, strategy, goals and anticipated milestones; the Company’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results/data may not be consistent with initial or preliminary results/data or results/data from prior preclinical studies or clinical trials; the Company’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the SEC on April 26, 2022, and elsewhere in the Company’s filings and reports with the SEC. Forward-looking statements contained in this Current Report on Form 8-K are made as of this date, and the Company undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

The information contained in this Current Report on Form 8-K is hereby incorporated by reference into the Company’s Registration Statement Form F-3 (Registration No. 333-266404).

 

Item 9.01

Financial Statements and Exhibits.

(d)

 

Exhibit
Number		    Exhibit Description
99.1    Press Release of the Company, dated February 16, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 17, 2023   AMBRX BIOPHARMA INC.
    By:  

/s/ Sonja Nelson

    Name:   Sonja Nelson
    Title:   Chief Financial and Operating Officer
 EX-99.1 2 d440404dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ARX517, Ambrx’s Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer

 

  •  

First clinical data from ongoing Phase 1 dose escalation trial (APEX-01) shows a prostate-specific antigen (PSA) decrease of > 50% reduction in PSA levels from baseline in 3 of 3 patients with metastatic prostate cancer receiving ARX517 at 2.0 mg/kg (Cohort 6)

 

  •  

2 of 3 patients in Cohort 6 experienced a greater than 90% reduction in PSA levels

 

  •  

No drug-related severe adverse events (SAEs) or dose limiting toxicities (DLTs) have been observed

 

  •  

These data provide early evidence of proof of concept for single-agent ARX517 as an ADC treatment for advanced prostate cancer

SAN DIEGO, February 16, 2023 – Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM) today announced encouraging initial data from its ongoing Phase 1 trial (APEX-01 (NCT04662580)) investigating ARX517, Ambrx’s proprietary anti-PSMA ADC, in prostate cancer patients. APEX-01 is a Phase 1, first-in-human, open label dose escalation and dose expansion trial enrolling patients with advanced prostate cancer whose tumors have progressed on at least two prior FDA-approved treatments. APEX-01 is the only ongoing clinical trial in the United States targeting PSMA with an ADC. APEX-01 opened for enrollment July 2021 and this is the first data being reported in the study.

In the Phase 1 dose-escalation portion of the study, ascending dose levels of ARX517 is administered as a single agent every 3 weeks. The primary endpoints are safety, tolerability and pharmacokinetics. The key secondary endpoint is objective decline of prostate-specific antigen (PSA) from baseline and/or tumor shrinkage. PSA is a protein produced by the prostate gland and is commonly used as a biomarker to diagnose and follow prostate cancer. A ≥ 50% reduction in PSA levels from baseline is considered clinically relevant and has been shown to correlate with improved overall survival in prostate cancer.

To date, 22 prostate cancer patients have been dosed across 7 dose level Cohorts starting from 0.32 mg/kg to 2.4 mg/kg. A minimum of 3 patients were enrolled at each Cohort. The dose limiting toxicity (DLT) period is 21 days.

  •  

Of 22 patients evaluable for safety, no drug-related severe adverse events (SAEs) or grade ≥3 treatment-related AEs have been observed. ARX517 was well-tolerated with grade 1 or 2 treatment-related adverse events being reported. The maximum tolerated dose (MTD) has not yet been reached.

 

  •  

PSA reductions of > 30% have been observed in Cohorts 2-5, beginning at the second to lowest dose, 0.64 mg/kg.

 

  •  

In Cohort 6 (2.0 mg/kg dose), 3 of 3 (100%) patients experienced a greater than 50% reduction in PSA levels. 2 of 3 patients experienced a greater than 90% reduction of PSA levels. One of three patients had soft tissue measurable disease and experienced a RECIST v1.1 partial response at the first on-treatment scan.

 

  •  

Three patients have been dosed in Cohort 7 with no DLTs.

“The preliminary data from patients with prostate cancer are highly encouraging,” said Dr. Michael Schweizer, MD, an Investigator on APEX-01 and Associate Professor Division of Medical Oncology, Fred Hutchinson Cancer Research Center. “Seeing a greater than 50% reduction in PSA levels in three of three patients at the 2.0 mg/kg dose level in this patient population is impressive, and ARX517 appears to be well tolerated so far. I am very optimistic for its future development. We look forward to more data from APEX-01, as the dose escalation continues in this difficult-to-treat patient population.”

The Safety Monitoring Committee (SMC) meeting to discuss the next dose Cohort is scheduled for the end of February 2023. Not all patients have undergone or completed tumor assessments and the data are not yet final.

Ambrx plans to report further information regarding ARX517 and the APEX-01 study at its upcoming Analyst and Investor Day scheduled for February 24, 2023. Additional data are planned for presentation at an upcoming medical meeting.

“While recent advances have considerably reduced the number of men who die from prostate cancer, it remains the second-most common form of death from cancer in the United States. Approximately 1 man in 41 will die of prostate cancer. Thus, there remains an urgent need for better treatments, in particular for men with advanced prostate cancer,” said Daniel J. O’Connor, CEO of Ambrx. “We are very pleased to see a significant reduction of greater than 50% in PSA levels in the first three patients at 2.0 mg/kg, two of which went on to see a greater than 90% PSA level reduction, without any serious drug-related adverse events.”

ARX517 is an antibody-drug conjugate composed of a fully humanized anti-PSMA mAb linked to AS269, a Ambrx proprietary potent microtubule inhibitor. ARX517 targets the prostate-specific membrane antigen (PSMA). PSMA is highly expressed (>89%) in Metastatic castration-resistant prostate cancer (mCRPC) and has been shown to be a validated therapeutic target.

Upon binding to PSMA on the surface of cancer cells, ARX517 is internalized and pAF-AS269, its cancer cell killing payload, is released following lysosomal metabolism. ARX517’s site-specific linkage, stable conjugation chemistry, and non-cleavable linker exhibit a homogenous drug-antibody-ratio, mAb-like biophysical properties, and exceptional stability. Therefore, we believe ARX517 can promote highly specific tumor cell killing with minimal off-target toxicity.

ARX517 has the potential to be a first- and best-in-class anti-PSMA ADC addressing the high unmet medical need in mCRPC.

About Ambrx Biopharma Inc.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit www.ambrx.com.

Forward-Looking Statements

This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “intend,” “plan,” and similar expressions, and include, without limitation, express or implied statements regarding Ambrx’s beliefs and expectations regarding the potential benefits of ARX517, clinical development and strategic plans for ARX517 and the timing of trial and data updates and milestones related to ARX517. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks

and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results/data may not be consistent with initial or preliminary results/data or results/data from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Annual Report on Form 20-F filed with the SEC on April 26, 2022, and elsewhere in Ambrx’s filings and reports with the SEC. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Contacts

INVESTORS

Mike Moyer

LifeSci Advisors

617-308-4306

mmoyer@lifesciadvisors.com

MEDIA

Mike Tattory

Account Supervisor

LifeSci Communications

media@ambrx.com

Source: Ambrx Biopharma, Inc.

###

EX-101.SCH 3 amam-20230216.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 amam-20230216_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 amam-20230216_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Phantom Share Units (PSUs) [Member] Phantom Share Units (PSUs) [Member] Adr [Member] Adr [Member] EX-101.PRE 6 amam-20230216_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g440404g0217033646916.jpg GRAPHIC begin 644 g440404g0217033646916.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Feb. 16, 2023
Document And Entity Information [Line Items]  
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001836056
Document Type 8-K
Document Period End Date Feb. 16, 2023
Entity Registrant Name Ambrx Biopharma Inc.
Entity Incorporation State Country Code E9
Entity File Number 001-40505
Entity Address, Address Line One 10975 Torrey Pines Road
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 729-3339
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Phantom Share Units (PSUs) [Member]  
Document And Entity Information [Line Items]  
Security Exchange Name NYSE
Security 12b Title Ordinary shares, par value US $0.0001 per share
Adr [Member]  
Document And Entity Information [Line Items]  
Security Exchange Name NYSE
Security 12b Title American Depositary Shares, each representing seven ordinary shares, par value US $0.0001 per share
Trading Symbol AMAM
XML 9 d440404d8k_htm.xml IDEA: XBRL DOCUMENT 0001836056 2023-02-16 2023-02-16 0001836056 us-gaap:PhantomShareUnitsPSUsMember 2023-02-16 2023-02-16 0001836056 dei:AdrMember 2023-02-16 2023-02-16 NYSE 00-0000000 false 0001836056 8-K 2023-02-16 Ambrx Biopharma Inc. E9 001-40505 10975 Torrey Pines Road La Jolla CA 92037 (858) 729-3339 false false false false Ordinary shares, par value US $0.0001 per share American Depositary Shares, each representing seven ordinary shares, par value US $0.0001 per share AMAM NYSE true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [dq-0546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName may have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context duration_2023-02-16_to_2023-02-16_us-gaap-StatementClassOfStockAxis_us-gaap-PhantomShareUnitsPSUsMember. d440404d8k.htm 7 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d440404d8k.htm 7 d440404d8k.htm amam-20230216.xsd amam-20230216_def.xml amam-20230216_lab.xml amam-20230216_pre.xml d440404dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d440404d8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "amam-20230216_def.xml" ] }, "inline": { "local": [ "d440404d8k.htm" ] }, "labelLink": { "local": [ "amam-20230216_lab.xml" ] }, "presentationLink": { "local": [ "amam-20230216_pre.xml" ] }, "schema": { "local": [ "amam-20230216.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 2, "nsprefix": "amam", "nsuri": "http://www.ambrx.com/20230216", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d440404d8k.htm", "contextRef": "duration_2023-02-16_to_2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d440404d8k.htm", "contextRef": "duration_2023-02-16_to_2023-02-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "amam_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.ambrx.com/20230216", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "amam_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.ambrx.com/20230216", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AdrMember": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "Adr [Member]", "terseLabel": "Adr [Member]" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_PhantomShareUnitsPSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Phantom Share Units (PSUs) [Member]", "terseLabel": "Phantom Share Units (PSUs) [Member]" } } }, "localname": "PhantomShareUnitsPSUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ambrx.com//20230216/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0001193125-23-041459-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-041459-xbrl.zip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end